So their physician says to the patient, hey, we got this whole genome sequencing test you should get it is actually a very reasonable price right now. We can do this with no advertising on our part. And so just imagine the unlimited demand that can come in from that and all we have to do, all we have to do is continue to build out our state-of-the-art lab that nobody in the country can compete with. It’s such an incredible statement. I can’t believe I’m making it, but I am making it and everybody remember this a year from now that I told you today, and I told you three months and six months ago, we are in the right place at the right time. And we are a leading, we are the leading lab in the country, in my opinion, and whole genome sequencing based on price.
Yes, you can go to other labs to get whole genome sequencing and it costs a fortune. But for the masses, it’s one whole genome sequencing it was always too expensive so nobody even considered it so it’s like a whole new industry it’s a whole new business. And it’s just starting up. So it’s interesting where the demand is coming from. It’s not just coming from academic institutions doing research. We’re having other types of interest. And it’s all coming out of the woodwork now that we have this great pricing. They’re saying, my God, we already have the platform to roll out your whole genome sequencing tests on potentially millions of patients. So we’re in the first inning of figuring this all out. There are going to be some growing pains for a couple of quarters.
But I’m telling you, if I know anything, I know there are Nebula Genomics business going to be incredibly valuable over the next six months to 12 months, 18 months. And if people really are long term investors is exactly what you want to invest in. But it’s just amazing. People love to buy high and sell low. So here we are, we have a low price stock. I don’t even want to talk about the stock as CEO, I don’t even think I should talk about the stock. And yet the stocks not trading, and people don’t understand the potential we have here. And as long as they don’t have to dilute the shareholders, the risk reward is phenomenal. So I hope, Hunter, I hope I answered your question. But I really love your support. And I really love your work. And so thanks for being on the call and asking those questions.
You have one more before I go to the next one?
Hunter Diamond: Absolutely. Yeah, that was my only question. I guess it sounds like from what I heard from you, that you’re seeing which I always thought made sense, the enterprise model is kind of the most efficient way. Meaning going to the bigger enterprises versus the D2C direct-to-consumer with ads, that one has worked, but it seems like the easier the layup is sort of reaching all these big telemedicine companies that already have the patients.
Ted Karkus : Hunter, you said it better than I could have that’s spot on. So I inherited when we acquired Nebula Genomics, I hire I inherited a direct-to-consumer model where you have to advertise. And then we built out a lab. So when we first bought the business, I don’t know the exact numbers probably around a breakeven business when we first bought — when we built a lab, we took an enormous amount of overhead and building the genomics lab, we also converted a COVID testing lab to some of the people transferred over. But understand now all of a sudden, we’re not doing COVID testing. And we have all the overhead and expenses of the genomics lab. And we’re not doing the business to support it. And so all of a sudden, we’re losing money.
And that’s the situation we’re in now. But what’s interesting is we’re coming to a point in time, where now that we built it, it’s only a matter of months, not quarters before that business starts to really take off. And you’re exactly right. It’s going after these bigger enterprises that that don’t require advertising that have the platforms and have access to thousands of physicians and millions of patients. And so that’s one of the main avenues that I’m excited about, not the only one. And again, academic institutions, and others also countries. There are countries that want to do whole genome sequencing on their population or percentage of their population. So there’s some monster opportunities out there. Now, as the pricing has come down significantly, people are starting to take notice.
Hunter, thank you so much. Let me go to the next question, we’re going to run out of time. And there’s still a couple of more questions here. Really appreciate your support, Hunter. Have a great day. Nick, if you got to the next question, please.
Operator: Thank you. Next question will be from Dennis Waldman of Barrett Productions LLC. Please go ahead.
Dennis Waldman : Hi, Ted. Thank you for a great presentation. I am a Nebula user. And I sometimes think that people don’t understand the capabilities and what is affordable to us as a user, the information we receive is just amazing. I think about the fact that there’s these million dollar researches on genetics going on. And I’m able to see how I fit into that. But I didn’t want to comment to reinforce what you’re saying is that my friends in the business and the research business, are telling me because of the drop in price that finally the genetic researchers have the amount that’s going on, it’s just exploding to this reconfirms what’s going on. And the fact that it’s being done domestically, it makes it so much attractive to Nebula.
So the question I have for you is, let’s, you talked about where we’re going to be a year from now. So I’m going to be more specific. We’re going to be on this conference call a year from now. What are you going to be telling me about Nebula and how profitable we are?
